Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Panobinostat in Pediatric, Adolescent and Young Adult Patients With Solid Tumors Including Osteosarcoma, Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid Tumors and Neuroblastoma

NCT04897880 is registered in ClinicalTrials.gov with Australian & New Zealand Children's Haematology/Oncology Group as lead sponsor.

NCT NCT04897880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04897880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Panobinostat in Pediatric, Adolescent and Young Adult Patients With Solid Tumors Including Osteosarcoma, Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid Tumors and Neuroblastoma
Lead sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Phase
Phase 2
Overall status
Terminated
Start date
January 9, 2019
Completion date
May 8, 2024
Enrollment
25 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumor, malignant rhabdoid tumor, recurrent brain tumor, childhood, rhabdoid tumor